UC-MSCs in Moderate and Severe Plaque Psoriasis

Phase 1, randomised trial of RegenSkin in plaque psoriasis (3 arms), sponsored by Tianjin Ever Union Biotechnology Co., Ltd. Primary endpoints: Proportion of subjects who have 75% or more reduction in Psoriasis Area and Severity Index at 20 weeks and Proportion of subjects who achieve a score of 0 or 1 on a 5-point Physician's Global Assessment at 20 weeks. Status: unknown.